Kousha Obaid, Gil Luis Cunha, Panggalo Idayani, Blaikie Andrew, Ellis John
University of St Andrews, St Andrews, UK
University of Manchester - The Victoria University of Manchester Campus, Manchester, UK.
BMJ Open. 2025 Jul 1;15(7):e095892. doi: 10.1136/bmjopen-2024-095892.
Globally, over a hundred million people are estimated to suffer from diabetic retinopathy (DR), which is a major complication of diabetes mellitus (DM). The prevalence of DM is projected to increase from the current 537 million by almost 50%, to 783 million by 2045. As a result, DR is one of the fastest rising causes of preventable blindness. Three out of four people suffering from DM live in low- and middle-income countries (LMICs), where resources for both diagnosis and treatment are lacking. There has been a reduction in the rate of blindness from DR in high-income countries, while an opposite trend has been noted in LMICs, contributing to this massive morbidity burden. This scoping review aims to ascertain the methods used to assess DR in LMICs.
The scoping review will adhere to the Preferred Reporting Items for Systematic Review and Meta-Analysis extension for Scoping Review (PRISMA-ScR) guidelines and the Arksey and O'Malley (2005) methodology framework. A systematic search of peer-reviewed literature will be carried out for all papers up to 15 May 2025 by identifying studies from electronic databases, including Embase, Medline and CENTRAL (Cochrane Library). A hand search of the associated reference lists of included studies and grey literature will also be conducted. The identified studies will be screened based on agreed eligibility (inclusion/exclusion) criteria by two independent reviewers, with any disagreements resolved via arbitration from a third reviewer. The data will be thematically summarised according to different aspects of DR assessment methods, and key findings will be elicited. The key findings will provide a comprehensive and clear understanding of the assessment methods used to identify DR in LMICs.
Ethical approval was not sought for this work as only publicly available information is used. The results will be disseminated through a peer-reviewed publication, conference presentations and meetings with stakeholders.
据估计,全球有超过一亿人患有糖尿病视网膜病变(DR),这是糖尿病(DM)的一种主要并发症。预计糖尿病的患病率将从目前的5.37亿增加近50%,到2045年达到7.83亿。因此,DR是可预防失明的上升速度最快的原因之一。四分之三的糖尿病患者生活在低收入和中等收入国家(LMICs),这些国家缺乏诊断和治疗资源。高收入国家因DR导致的失明率有所下降,而LMICs则出现了相反的趋势,这加剧了这种巨大的发病负担。本范围综述旨在确定LMICs中用于评估DR的方法。
本范围综述将遵循系统评价与Meta分析扩展版的首选报告项目(PRISMA-ScR)指南以及阿克西和奥马利(2005年)的方法框架。通过从电子数据库(包括Embase、Medline和CENTRAL(Cochrane图书馆))中识别研究,对截至2025年5月15日的所有同行评审文献进行系统检索。还将对纳入研究的相关参考文献列表和灰色文献进行手工检索。由两名独立评审员根据商定的合格标准(纳入/排除)对识别出的研究进行筛选,任何分歧将通过第三名评审员的仲裁解决。数据将根据DR评估方法的不同方面进行主题总结,并得出关键结果。这些关键结果将全面、清晰地呈现用于在LMICs中识别DR的评估方法。
由于仅使用公开可用信息,因此未为本研究寻求伦理批准。研究结果将通过同行评审出版物、会议报告以及与利益相关者的会议进行传播。